# Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct03793179/  
OnCo record `nct03793179` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of carboplatin, pembrolizumab and pemetrexed in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.

## Summary

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT03793179 by National Cancer Institute (NCI), with a registry enrolment figure of 600 participants, started 2019-04-05 and due to reach its primary completion in 2027-09-30. Interventions recorded: Biospecimen Collection; Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Pembrolizumab; Pemetrexed; Positron Emission Tomography. Conditions listed: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "* Patients must have histologically or cytologically confirmed stage IV non-squamous non-small cell lung cancer (NSCLC) (includes M1a, M1b, and M1c stage disease, American Joint Committee on Cancer \[AJCC\] 8th edition)". Sites: Canada, Guam, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT03793179
- Phase: 3
- Setting: EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker Signature-Driven Analysis
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT03793179: https://clinicaltrials.gov/study/NCT03793179

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03793179.json